Based on the WisdomTree BioRevolution UCITS ETF - USD Acc GBP stock forecast from 0 analysts, the average analyst target price for WisdomTree BioRevolution UCITS ETF - USD Acc GBP is not available over the next 12 months. WisdomTree BioRevolution UCITS ETF - USD Acc GBP’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of WisdomTree BioRevolution UCITS ETF - USD Acc GBP is Very Bearish, which is based on 0 positive signals and 3 negative signals. At the last closing, WisdomTree BioRevolution UCITS ETF - USD Acc GBP’s stock price was GBX 1,318.20. WisdomTree BioRevolution UCITS ETF - USD Acc GBP’s stock price has changed by +0.60% over the past week, -10.32% over the past month and -9.13% over the last year.
No recent analyst target price found for WisdomTree BioRevolution UCITS ETF - USD Acc GBP
No recent average analyst rating found for WisdomTree BioRevolution UCITS ETF - USD Acc GBP
Company Overview WisdomTree BioRevolution UCITS ETF - USD Acc GBP
Stock Target Advisor's fundamental analysis for WisdomTree BioRevolution UCITS ETF - USD Acc GBP's stock is Very Bearish.
Unfortunately we do not have enough data on WBIO:LSE's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on WBIO:LSE's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on WBIO:LSE's stock to indicate if its overvalued.
The last closing price of WBIO:LSE's stock was GBX 1,318.20.
The most recent market capitalization for WBIO:LSE is GBX 6.95M.
Unfortunately we do not have enough analyst data on WBIO:LSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains WisdomTree BioRevolution UCITS ETF - USD Acc GBP's stock.
Sorry, we do not have any data on the number of employees for WisdomTree BioRevolution UCITS ETF - USD Acc GBP.
Sorry we do not have any infomation available on WisdomTree BioRevolution UCITS ETF - USD Acc GBP's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for WBIO:LSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
